Bristol Myers Squibb entered the second quarter of 2025 with results that confirm its ability to grow through a strong innovation portfolio while facing pressures associated with the lingering impact of patent expirations and one-time costs. The company reported stable total revenues and strong growth in key growth products, although net income and earnings per share were negatively impacted by costs related to the strategic partnership with BioNTech.

The company also raised its full-year revenue guidance and reaffirmed its commitment to delivering innovation in oncology, cardiology and immunology. The move shows that Bristol Myers Squibb $BMY is focused on a long-term strategy that builds on portfolio expansion and the ability to generate stable cash flow for shareholders, despite short-term fluctuations.

How was the last quarter?

Total revenue in the second quarter was $12.3 billion, up 1% year-over-year. Adjusted for currency effects, revenue was more or less flat. A major difference…